Marinus Pharmaceuticals, Inc. (LON: 0JYL)

Market Cap	24.42M
Revenue (ttm)	23.48M
Net Income (ttm)	-104.82M
Shares Out	n/a
EPS (ttm)	-1.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,389
Average Volume	17,858
Open	0.540
Previous Close	0.539
Day's Range	0.540 - 0.544
52-Week Range	0.182 - 9.084
Beta	n/a
RSI	65.53
Earnings Date	Mar 6, 2025

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABA...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 166
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JYL

Financial Performance

In 2023, Marinus Pharmaceuticals's revenue was $30.99 million, an increase of 21.63% compared to the previous year's $25.48 million. Losses were -$141.41 million, 613.6% more than in 2022.

Financial numbers in USD